Program
Safiglipron
Also written as “HRS-7535”, “HRS-7535 tablet” and “HRS-7535 Tablets”.
In Jiangsu HengRui Medicine’s pipeline, GLP-1
. Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Renal Insufficiency, Chronic · Diabetic Nephropathies, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 193 open or running | phase 3since Sep 6, 2024 | Apr 20, 2022 | Dec 2026phase 2 · NCT06820099 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-7535
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Apr 20, 2022.
- May 14, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06422039 · 24 enrolled · China
- Jul 3, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06495931 · 24 enrolled · China
- Sep 6, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06589765 · 810 enrolled · China
- Sep 29, 2024Phase 2 study in OverweightNCT06621316 · 74 enrolled · China
- Oct 23, 2024Phase 2 study in Chronic Weight ManagementNCT06671821 · 81 enrolled · China
- Nov 1, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06672172 · 284 enrolled · China
- Dec 6, 2024Phase 1 study in Diabetes MellitusNCT06727838 · 18 enrolled · China
- Feb 5, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT06819488 · 6 enrolled · China
- Feb 6, 2025Phase 2 study in ObesityNCT06820099 · 225 planned · China
- Mar 25, 2025Phase 3 study in OverweightNCT06904105 · 556 enrolled · China
- May 6, 2025Phase 1 study in Diabetes MellitusNCT06961643 · 24 enrolled · China
- Nov 26, 2025Phase 1 study in ObesityNCT07269756 · 40 enrolled · China
- Jan 29, 2026Named safiglipronINNProposed as its International Nonproprietary Name in WHO's List 134 · before, HRS-7535
- Apr 7, 2026Phase 3 study in ObesityNCT07528027 · 648 planned · China
- May 29, 2026Phase 3 study in Renal Insufficiency, ChronicNCT07625774 · 3,690 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in ObesityNCT06820099
- Dec 2027Primary completion: phase 3 study in ObesityNCT07528027
- May 2031Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT07625774
TargetBeta
“GLP-1”the company's pipeline, read by Claude · source
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| brenipatide | Eli Lilly | phase 3 | 19 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07625774Renal Insufficiency, Chronic · China | 3 | Not yet recruiting | May 2031 | 3,690 |
| NCT07528027Obesity · China | 3 | Recruiting | Dec 2027 | 648 |
| NCT07269756Obesity · China | 1 | Completed | Mar 8, 2026 | 40 |
| NCT06961643Diabetes Mellitus · China | 1 | Completed | Jan 22, 2026 | 24 |
| NCT06904105Overweight · China | 3 | Completed | Apr 17, 2026 | 556 |
| NCT06820099Obesity · China | 2 | Recruiting | Dec 2026 | 225 |
| NCT06819488Diabetes Mellitus, Type 2 · China | 1 | Completed | Apr 16, 2025 | 6 |
| NCT06727838Diabetes Mellitus · China | 1 | Completed | Jan 25, 2025 | 18 |
| NCT06672172Diabetes Mellitus, Type 2 · China | 3 | Completed | Nov 13, 2025 | 284 |
| NCT06671821Chronic Weight Management · China | 2 | Completed | Aug 15, 2025 | 81 |
| NCT06621316Overweight · China | 2 | Completed | Jul 14, 2025 | 74 |
| NCT06589765Diabetes Mellitus, Type 2 · China | 3 | Completed | May 29, 2026 | 810 |
| NCT06495931Diabetes Mellitus, Type 2 · China | 1 | Completed | Aug 13, 2024 | 24 |
| NCT06422039Diabetes Mellitus, Type 2 · China | 1 | Completed | Aug 6, 2024 | 24 |
| NCT06415214Diabetic Nephropathies · China | 2 | Completed | Jul 15, 2025 | 281 |
| NCT06393348Diabetes Mellitus, Type 2 · China | 2 | Completed | Nov 15, 2024 | 155 |
| NCT06132204Diabetes Mellitus, Type 2 · China | 1 | Completed | Mar 13, 2024 | 16 |
| NCT05759897Diabetes Mellitus, Type 2 | 2 | UNKNOWN | Dec 21, 2023 | 180 |
| NCT05347758Healthy Subjects | 1 | UNKNOWN | Sep 18, 2022 | 106 |
How it is read
Names in the registry
- “HRS-7535”, 7 entries
- “HRS-7535 tablet”, 5 entries
- “HRS-7535 Tablets”, 3 entries
- “HRS-7535 tablets”, 2 entries
- “HRS-7535 Tablet”, 1 entry
Codes read as this program: HRS7535.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 8 studies
- Obesity, 5 studies
- Diabetes Mellitus, 2 studies
- Renal Insufficiency, Chronic, 1 study
- Diabetic Nephropathies, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.